Market Place
Sourcing Support
Cabaletta Bio to Attend December Investor Conferences
26 Nov 2024 //
GLOBENEWSWIRE
Cabaletta Bio Presents Positive CABA-201 Safety & Efficacy at ACR
18 Nov 2024 //
GLOBENEWSWIRE
Cabaletta Bio Reports Q3 2024 Financial & Business Update
14 Nov 2024 //
GLOBENEWSWIRE
Cabaletta Bio to Attend Guggenheim Healthcare Innovation Conference
06 Nov 2024 //
GLOBENEWSWIRE
Cabaletta Bio To Present CABA-201 Data At ACR Convergence
25 Sep 2024 //
GLOBENEWSWIRE
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
28 Aug 2024 //
GLOBENEWSWIRE
Cabaletta Bio Reports Q2 2024 Results And Provides Business Update
08 Aug 2024 //
GLOBENEWSWIRE
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
02 Jul 2024 //
GLOBENEWSWIRE
Cabaletta`s early data signal CAR-T potential in inflammatory diseases
15 Jun 2024 //
PRESS RELEASE
Cabaletta Reports Initial CABA-201 Data In Myositis And SLE
14 Jun 2024 //
GLOBENEWSWIRE
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
29 May 2024 //
GLOBENEWSWIRE
Cabaletta Bio Reports Q1 2024 Financials, Business Update
15 May 2024 //
GLOBENEWSWIRE
Cabaletta Bio To Participate In H.C. Wainwright BioConnect Conference
13 May 2024 //
GLOBENEWSWIRE
3 Stocks with Growth Prospects in the Triple Digits
29 Apr 2024 //
AOL
Additional drugmakers flag risks working with WuXi amid heightened US scrutiny
02 Apr 2024 //
ENDPTS
Cabaletta Reports Q4 and FY23 Financial Results and Provides Business Update
21 Mar 2024 //
GLOBENEWSWIRE
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201
20 Mar 2024 //
GLOBENEWSWIRE
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
27 Feb 2024 //
GLOBENEWSWIRE
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201
01 Feb 2024 //
GLOBENEWSWIRE
Cabaletta to Participate in Guggenheim Healthcare Talks 6th Annual Conference
31 Jan 2024 //
GLOBENEWSWIRE
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201
08 Jan 2024 //
GLOBENEWSWIRE
Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
GLOBENEWSWIRE
Cabaletta Bio to Participate in 6th Annual Evercore ISI HealthCONx Conference
28 Nov 2023 //
GLOBENEWSWIRE
Cabaletta Bio Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application
06 Nov 2023 //
GLOBENEWSWIRE
Cellares to produce Cabaletta’s autoimmune CAR-T candidate
06 Nov 2023 //
ENDPTS
Cabaletta to Participate in Multiple Upcoming Investor Conferences in November
30 Oct 2023 //
GLOBENEWSWIRE
Cabaletta Bio Receives FDA Clearance of IND Application with CABA-201
02 Oct 2023 //
GLOBENEWSWIRE
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
19 Sep 2023 //
GLOBENEWSWIRE
Here`s Why We`re Not Too Worried About Cabaletta Bio`s Cash Burn Situation
12 Sep 2023 //
SIMPLY WALL
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in Sep
30 Aug 2023 //
GLOBENEWSWIRE
Cabaletta Bio and WuXi Announce Expansion of GMP Agreement to Include CABA-201
22 Aug 2023 //
GLOBENEWSWIRE
Cabaletta Bio Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Cabaletta Appoints Commercial Leader Shawn Tomasello to Board of Directors
24 Jul 2023 //
GLOBENEWSWIRE
Why Shares of Cabaletta Bio Are Up Tuesday
18 Jul 2023 //
FOOL
Cabaletta Bio to Present at the Jefferies Healthcare Conference
31 May 2023 //
GLOBENEWSWIRE
Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock
22 May 2023 //
GLOBENEWSWIRE
Cabaletta lands $84M from stock sale after FDA clears INDs for CD19
18 May 2023 //
ENDPTS
Cabaletta Bio Announces Proposed Public Offering of Common Stock
17 May 2023 //
GLOBENEWSWIRE
Cabaletta Bio Announces Pricing of Public Offering of Common Stock
17 May 2023 //
GLOBENEWSWIRE
Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201
16 May 2023 //
PRESS RELEASE
Cabaletta Bio Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Cabaletta Bio to Present at the American Society of Gene and Cell Therapy
02 May 2023 //
GLOBENEWSWIRE
Cabaletta’s CAR-T therapy for lupus earns key FDA designation
01 May 2023 //
CIINICAL TRIALS ARENA
Cabaletta Bio Receives FDA Fast Track Designation for CABA-201
01 May 2023 //
GLOBENEWSWIRE
Cabaletta Bio to Present at the H.C. Wainwright BioConnect Conference
25 Apr 2023 //
GLOBENEWSWIRE
Cabaletta Bio to Present at 22nd Annual Needham Virtual Healthcare Conference
13 Apr 2023 //
GLOBENEWSWIRE
Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201
31 Mar 2023 //
GLOBENEWSWIRE
Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results
16 Mar 2023 //
GLOBENEWSWIRE
Cabaletta Bio to Present at the Cowen 43rd Annual Health Care Conference
28 Feb 2023 //
GLOBENEWSWIRE
Cabaletta Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
05 Jan 2023 //
GLOBENEWSWIRE
Cabaletta Bio Announces $35 Million Offering
08 Dec 2022 //
GLOBENEWSWIRE
Cabaletta Bio to Present at the 5th Annual Evercore ISI HealthCONx Conference
22 Nov 2022 //
GLOBENEWSWIRE
IASO & Cabaletta Announce License Agreement for Clinically Validated CD19 Binder
11 Oct 2022 //
PRNEWSWIRE
Cabaletta Bio Announces CABA-201,Newly CD19-Targeting CAR T Cell Therapy
11 Oct 2022 //
GLOBENEWSWIRE
Cabaletta Bio to Present at the 29th Annual Congress of the European Society
06 Oct 2022 //
GLOBENEWSWIRE
Cabaletta Bio to Present at the Chardan 6th Annual Genetic Medicines Conference
26 Sep 2022 //
GLOBENEWSWIRE
Cabaletta Bio Presents New Interim Data from the DesCAARTes™ Ph1 Trial
10 Sep 2022 //
GLOBENEWSWIRE
Cabaletta Bio to Present Data on DesCAARTes Trialat at the 31st EADV Congress
29 Aug 2022 //
GLOBENEWSWIRE
Cabaletta Bio Reports Q2 2022 Rusult and Provides Business Update
11 Aug 2022 //
GLOBENEWSWIRE
